EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting–Adjusted Comparison to a Historical Control Group Treated With Belimumab

Chong Luo iD, Shu Su, Jingyue Liu, Junyu Lin, Jin Song, Zongwen Chen, Yuanyuan Peng, Lijun Jiang, Meng Jia, Li Wang, Xinhui Jiang, Wei Zhang und 4 weitere

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.43417 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Chong Luo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health an…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key R&D Program of China (2021YFC2702000), Kuanren Talent programs of the second affiliated hospital of Chongqing Medical University (202417-16), National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.

Methods

We performed a prospective cohort study across seven tertiary hospitals in China, enrolling patients aged 5 to 18 years with cSLE. Primary endpoints included the proportions of patients attaining Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) at 3, 6, and 12 months after treatment, complemented by relapse rates and steroid tapering metrics. Propensity score–based inverse probability of treatment weighting (IPTW) was employed to address baseline imbalances between the telitacicept group (n = 60) and the historical control group treated with belimumab (n = 67).

Results

Among 60 enrolled patients (median follow‐up 12 [interquartile range 6–12] months), LLDAS and DORIS achievement rates progressively increased from 19.6% and 7.8% at 6 months to 65.7% and 37.1% at 12 months. Flare rates remained low (3 months: 1.7%; 6 months: 11.8%; 12 months: 14.3%). Notably, 74.3% of patients achieved prednisone doses ≤7.5 mg/day by 12 months (vs baseline 13.3%, P < 0.0001). IPTW‐adjusted analyses demonstrated comparable efficacy between the telitacicept and belimumab groups across all endpoints in terms of LLDAS and DORIS attainment, steroid reduction, and immunologic normalization (all P > 0.05).

Conclusion

Telitacicept combined with SoC exhibited significant improvements in disease activity, steroid reduction, and immunologic markers, with therapeutic outcomes comparable to belimumab in cSLE management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsHumansChildFemaleAdolescentMaleProspective StudiesTreatment OutcomeChild, PreschoolDrug Therapy, CombinationRemission InductionPropensity ScoreChinaRecombinant Fusion Proteins

Substanzen

belimumabAntibodies, Monoclonal, HumanizedImmunosuppressive AgentstelitaciceptRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development…
  • Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.
  • Department of Epidemiology and Biostatistics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Pediatrics, The First People's Hospital of Yunnan Province, Kunming, China.
  • Department of Nephrology & Rheumatology, The Affiliated Children's Hospital of Kunming Medical University, Kunming Children's Hospital, Kunming, China.
  • Department of Rheumatology Immunization, Guiyang Maternal and Child Health Care Hospital, Guiyang, China.

ORCID-Profile: Chong Luo, Xuemei Tang

Förderung

  • National Key R&D Program of China (2021YFC2702000)
  • Kuanren Talent programs of the second affiliated hospital of Chongqing Medical University (202417-16)
  • National Key Research and Development Program of China

Zitieren

APA

Luo, C., Su, S., Liu, J., Lin, J., Song, J., Chen, Z., Peng, Y., Jiang, L., Jia, M., Wang, L., Jiang, X., Zhang, W., Rong, Z., Zhao, B., Wang, Y., & Tang, X. (2026). Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting–Adjusted Comparison to a Historical Control Group Treated With Belimumab. Arthritis & Rheumatology. https://doi.org/10.1002/art.43417

Vancouver

Luo C, Su S, Liu J, Lin J, Song J, Chen Z, et al. Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting–Adjusted Comparison to a Historical Control Group Treated With Belimumab. Arthritis & Rheumatology. 2026. doi:10.1002/art.43417

BibTeX
@article{Luo2026,
  author = {Luo, Chong and Su, Shu and Liu, Jingyue and Lin, Junyu and Song, Jin and Chen, Zongwen and Peng, Yuanyuan and Jiang, Lijun and Jia, Meng and Wang, Li and Jiang, Xinhui and Zhang, Wei and Rong, Zanhua and Zhao, Bo and Wang, Yajun and Tang, Xuemei},
  title = {Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting–Adjusted Comparison to a Historical Control Group Treated With Belimumab},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.43417}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche